Clinical Trial Update: An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating omega-3 free fatty acids (Epanova) for maintenance of symptomatic remission in Crohn's disease; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Epanova (icosapent ethyl)

Snippet

Sponsor: Tillotts Pharma AG | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED